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1. Abstract  1.1. Zusammenfassung  Die Entwicklung von selektiven und sicheren Wirkstoffen ist eine wichtige Aufgabe in der pharmazeutischen Forschung und in den letzten 25 Jahren sind biophysikalische Methoden zur Charakterisierung von Protein-Ligand Wechselwirkungen zu einem wichtigen Hilfsmittel entwickelt worden. Zum einem erlauben diese Methoden eine Verifizierung von in Hochdurchsatzverfahren identifizierten Molekülen und zum anderen ergänzen sie traditionelle Ansätze zum Wirkstoffdesign, durch tiefe Einblicke in die Thermodynamik, Kinetik und den Mechanismus der Interaktion. Basierend auf diesen Informationen wurden Rationalen entwickelt, die zur Identifizierung von vielversprechenden Leitstrukturen genutzt werden können.  Histondeacetylasen (HDACs) sind eine Familie von Proteinen, die intensiv als therapeutische Ziele für die Behandlung von verschiedenen Krankheiten, unter anderem Krebs, neurodegenerativen Krankheiten und parasitäreren Infektionen untersucht werden. Sie katalysieren die Deacetylierung der ε-Aminofunktion von Lysinen von Histonen und anderen Proteinen, wodurch sie wichtige Funktionen in der epigenetischen Regulation ausüben. Mit SAHA, FK228, PXD101 und LBH589 wurden vier Histondeacetylase-Inhibitoren zur Behandlung von verschiedenen Tumorerkrankungen zugelassen. Diese verursachen zahlreiche Nebenwirkungen. SAHA, PXD101 und LBH589 sind unspezifische Inhibitoren, die nahezu alle Isotypen der HDACs hemmen. Durch eine Entwicklung von selektiven Inhibitoren sollen Nebenwirkungen minimiert werden und gleichzeitig eine spezifischere Therapie ermöglicht werden. Die vorliegende Arbeit beschäftigt sich mit der Frage, inwieweit Informationen aus der Analyse der Thermodynamik, Kinetik und Bindemechanismen genutzt werden können, um die Selektivität von Inhibitoren der HDAC-Familie zu beschreiben. Die im Rahmen dieser Doktorarbeit erzielten Ergebnisse sind im kumulativen Teil, bestehend aus fünf in begutachteten Zeitschriften publizierten Artikeln und einer zur Begutachtung eingereichten Publikation, dargestellt. Sie liefern zum einen Beiträge zur Methodik der Identifizierung und biophysikalischen Charakterisierung von Histondeacetylase-Inhibitoren, und zum anderen tragen sie zum tiefen Verständnis der molekularen Grundlagen der Inhibition von HDACs im Speziellen und von Protein-Ligand-Wechselwirkungen im Allgemeinen bei.   Der erste Teil dieser Arbeit beinhaltet Methodenentwicklungen zur Identifizierung und biophysikalischen Charakterisierung von Histondeacetylase-Inhibitoren. In einer Kooperation mit der Arbeitsgruppe von Herrn Prof. Wessig von der Universität Potsdam wurden Liganden entwickelt, deren Fluoreszenzlebensdauer sich bei der Bindung an HDACs ändert. Über eine Verdrängungsreaktion kann die Bindung von Histondeacetylase-Inhibitoren bestimmt werden. Ein daraus entwickelter kompetitiver 
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Bindeassay ist für Anwendungen im Hochdurchsatz-Screening und zur Bestimmung von Bindekonstanten hervorragend einsetzbar. Ferner eignet sich der erstellte Assay auch für Anwendungen mit Klasse IIa HDACs, womit der erste Bindeassay für diese Klasse entwickelt werden konnte.  Zur Ermittlung von kinetischen Parametern und des Mechanismus der Bindung von Inhibitoren an HDACs wurde ein bestehender fluoreszenzspektroskopischer Bindeassay modifiziert, sodass zeitaufgelöst die Bindung von nichtfluoreszenten Liganden gemessen werden kann. Die ermittelten Kinetiken wurden mit einer globalen Fitanalyse analysiert. Mit dieser Methodik wurden die Reaktionsmechanismen für die Bindung von vier verschiedenen Liganden an die humanen HDACs 1, 6 und 8 sowie an eine bakterielle Histondeacetylase-ähnliche Amidohydrolase ermittelt.  Im zweiten Teil dieser Arbeit wurde am Beispiel der Histondeacetylase-ähnlichen Amidohydrolase aus Pseudomonas aeruginosa, HDAHpa, evaluiert, welche strukturellen Eigenschaften von Histondeacetylase-Inhibitoren die Selektivität beeinflussen und inwiefern mechanistische und thermodynamische Parameter zur Bewertung der Selektivität verwendet werden können. Hierzu wurden die Reaktionsmechanismen und die thermodynamische Signatur von strukturverwandten Inhibitoren des bekannten Histondeacetylase-Inhibitor N-Hydroxy-N′-phenyloctandiamid (SAHA) bestimmt, und deren Selektivität gegen die humanen HDACs 1–8 ermittelt. Im Allgemeinen zeigen SAHA und andere Liganden mit Hydroxamsäuren als zinkbindende Gruppe eine gute Selektivität gegenüber HDACs der Klasse IIa. Demgegenüber besitzt SATFMK, bei dem die Hydroxamsäurefunktion gegen eine Trifluormethylcarbonylgruppe ausgetauscht ist, eine gute bis sehr gute Selektivität gegen die HDACs 1–3 und 6, aber eine geringere Selektivität gegenüber HDACs der Klasse IIa und HDAC8. Mit einer mindestens 1000fachen Selektivität gegenüber den humanen HDACs konnte die höchste Selektivität für HDAHpa beim Liganden PFSAHA beobachtet werden. Dieser besitzt eine im Vergleich zu SAHA und SATFMK sterisch anspruchsvollere perfluorierte Alkylkette. Ferner wurde in einer weiteren Studie festgestellt, dass die hohe Selektivität von PFSAHA bei einer Variation der Kopfgruppe in vielen Fällen erhalten bleibt und durch Methylierung oder Chlorierung noch gesteigert werden kann.  Überraschenderweise, ergab eine Analyse der Bindemechanismen, dass PFSAHA und SATFMK je an andere Proteinkonformationen binden als die übrigen Liganden. Diese Ergebnisse unterstützen die These, dass selektive Liganden anhand ihres Bindemechanismus identifiziert werden können.  Zur Vertiefung des Verständnisses der molekularen Erkennung von Inhibitoren durch HDAHpa wurden die Bindungsreaktionen mittels isothermer Titrationskalorimetrie untersucht. Die Bestimmung der thermodynamischen Parameter zeigte, dass die Bindung von PFSAHA an HDAHpa mit einer unvorteilhaften Entropieänderung ausschließlich über enthalpische Beiträge erfolgt, während bei SATFMK die enthalpischen und entropischen Beiträge ausgeglichen sind. Dies deutet in der Tat darauf 
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hin, dass der enthalpische Beitrag bei selektiven Liganden höher ausgeprägt ist. Dennoch hat sich gezeigt, dass der enthalpische Beitrag zur Bindungsreaktion nur bedingt zur Vorhersage der Selektivität von Histondeacetylase-Inhibitoren geeignet ist. Erst eine neu definierte enthalpiegewichtete Bindekonstante zeigt eine gute Korrelation zur bestimmten Selektivität der Histondeacetylase-Inhibitoren. Allerdings müssen die Anwendbarkeit und Übertragbarkeit dieses empirischen Parameters für andere Proteintargets noch evaluiert werden. In einer weiteren Studie wurde die Bindung von PFSAHA und SATFMK an HDAHpa und eine zu HDAHpa homologe Histondeacetylase-ähnlichen Amidohydrolase aus Bordetella/Alcaligenes durch Proteinkristallographie und isothermer Titrationskalorimetrie detaillierter untersucht. Es konnte ermittelt werden, dass die Flexibilität und die Zugänglichkeit der Bindetasche einen wesentlichen Einfluss auf die Thermodynamik und den Mechanismus der Bindung hat. Bei einer besseren Zugänglichkeit und einer erhöhten Flexibilität erfolgt die Bindung in einer apparenten Einschritt-Reaktion und mit einem  höheren enthalpischen Beitrag zur Bindungsreaktion. Dieser wird allerdings durch Enthalpie-Entropie-Kompensation ausgeglichen, sodass es zu keiner Veränderung der Affinität kommt. Diese Ergebnisse erscheinen außerordentlich wichtig für die Entwicklung von Histondeacetylase-Inhibitoren, da HDACs mit vielen Proteinen interagieren und es wahrscheinlich ist, dass dies die Flexibilität der HDACs und damit die Ligandenbindung beeinflusst. Zusammenfassend zeigen diese Studien, dass eine bloße Betrachtung der Thermodynamik für die Identifizierung von selektiven Liganden im Allgemeinen nicht ausreicht, aber besonders in Verbindung mit mechanistischen Untersuchungen wertvolle Informationen über die potentielle Selektivität von Wirkstoffen liefert und vorhandene Parameter zur frühen Identifikation der Wirkstoffkandidaten mit der höchsten Erfolgswahrscheinlichkeit ergänzt.   1.2. Abstract  The development of selective and save compounds is an important task in drug discovery and during the past 25 years biophysical methods for the characterization of protein-ligand interactions have been developed to a valuable tool. On the one hand these methods allow to validate screening hits and on the other hand they complement traditional approaches in drug discovery by providing deep insights into the thermodynamics, kinetics and the mechanism of molecular interactions. Based on these information, approaches were developed which allow to identify promising lead structures for further development. Histone deacetylases (HDACs) are a protein family which are investigated as therapeutic targets for the treatment of different diseases like cancer neurodegenerative disorders and parasitic infections. By catalyzing the deacetylation of the ε-amino function of lysines of histones and other proteins they fulfill an important function for the epigenetic regulation. With SAHA, FK228, PXD101 and LBH589 four HDAC inhibitors were approved for the treatment of different cancers. They cause several 
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unwanted side effects. SAHA, PXD101 and LBH589 are unselective inhibitors which inhibit most HDAC isotypes. In order to minimize unwanted side effects and to provide a more specific therapy isotype selective inhibitors are developed. The present work deals with the question how information from an analysis of the thermodynamics, kinetics and binding mechanisms can be exploited to characterize the selectivity of inhibitors of the HDAC family. The generated results of this doctoral thesis are provided in the cumulative part which consists of five articles published in peer reviewed journals and one article submitted for peer review. One the one hand they extend the methodology on the identification and biophysical characterization of HDAC inhibitors and on the other hand they contribute to the deep comprehension of the molecular basis of the inhibition of HDACs and of protein-ligand interactions.  The first part of this work covers methods developed for the identification and biophysical characterization of HDAC inhibitors. In a cooperation with the research group of Prof. Wessig at the University of Potsdam ligands were generated whose fluorescence lifetime change upon binding to histone deacetylases. By a displacement of the ligands from the active site the binding of HDAC inhibitors can be monitored. A developed competitive binding assay is outstandingly suited for high throughput screening applications and the determination of binding constants. Furthermore, the developed assay is also applicable for class IIa HDACs resulting in the first binding assay for this HDAC class.  For the determination of kinetic parameters and the binding mechanism of the binding inhibitors to histone deacetylases an established fluorescence spectroscopic binding assay was modified, so that a time-resolved monitoring of the binding of nonfluorescent ligands is allowed. The determined kinetic traces were subjected to a global fit analysis. With this method the reaction mechanisms of the binding of four ligands to the human histone deacetylases 1, 6 and 8 as well as to a bacterial histone deacetylase-like amidohydrolase were evaluated.   In the second part of this work it was evaluated on the basis of a histone deacetylase-like amidohydrolase from Pseudomonas aeruginosa, HDAHpa, which structural elements of HDAC inhibitors affect the selectivity and how mechanistic and thermodynamic parameters can be applied to assess the selectivity. Therefore, the reaction mechanisms and the thermodynamic signature of structurally related inhibitors of the known HDAC inhibitor N-hydroxy-N′-phenyloctanediamide (SAHA) were determined and evaluated for their selectivity against the human histone deacetylases 1–8. Generally, SAHA and other compounds with a hydroxamic acid as zinc binding moiety exhibit a good selectivity against class IIa HDACs. In contrast, the compound SATFMK, where the hydroxamic acid moiety is exchanged by a trifluoromethyl ketone moiety, exhibits a good to very good selectivity against the HDACs 1–3 and 6 but a lower selectivity against class IIa HDACs and HDAC8. With an at least 1000-
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fold selectivity over human HDACs the highest selectivity was determined for the compound PFSAHA. This compound exhibits, compared to SAHA and SATFMK, a sterically more demanding perflourinated spacer. Furthermore, it was determined in another study that upon an exchange of the cap group the high selectivity is preserved in most cases and can be improved by methylation and chlorination.  Surprisingly, an analysis of the determined binding mechanisms suggests that PFSAHA and SATFMK bind each to other protein conformations as the other ligands. These results support the assumption that selective ligands can be identified on the basis of their binding mechanism.  In order to deepen the knowledge about the molecular recognition of inhibitors by HDAHpa the binding reactions were studied by isothermal titration calorimetry. The determination of the thermodynamic parameters revealed that the binding of PFSAHA to HDAHpa occurs with unfavorable entropic contributions and is solely enthallpically driven, while for the binding of SATFMK the entropic and enthalpic contributions are balanced. This indicates indeed that for selective binders the enthalpic contributions are more pronounced. However, the enthalpic contributions to binding are of limited suitability for the prediction of the selectivity of HDAC inhibitors. Only a newly defined enthalpy weighted binding constant exhibits a good correlation to the determined selectivity of the HDAC inhibitors. Certainly, the applicability and transferability to other protein targets have yet to be evaluated. In a further study, the binding of PFSAHA and SATFMK to HDAHpa and a to HDAHpa homologous histone deacetylase-like amidohydrolase from Bordetella/Alcaligenes were investigated in more detail by protein crystallography and isothermal titration calorimetry. It was shown, that the thermodynamic signature and the mechanism of the binding reaction is largely influenced by flexibility and accessibility of the active site. With a better accessibility and a higher flexibility the binding occurs in an apparent one-step reaction and with more favorable enthalpic contributions to binding. But these are balanced by enthalpy-entropy compensation resulting in an unchanged binding affinity. These findings seem to be exceptionally important for the development of HDAC inhibitors, since HDACs interact with several proteins and it is likely that these interactions alter the flexibility of the HDACs and with it the recognition of ligands. Taken together these studies indicate that generally a solely consideration of thermodynamic signatures is insufficient for the identification of selective compounds, but especially in combination with mechanistic investigations useful information about the potential selectivity of compounds are provided, which supplement existing parameters for the early identification of leads with a high probability of success.                   
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2. Introduction  2.1. Biophysical characterization of protein-ligand interactions  The rational development of save and selective compounds is a major task in drug discovery and during the past 25 years biophysical methods evolved to be key technologies for the characterization of proteins and protein-ligand interactions.[1] Biophysical methods are nowadays successfully applied for the quality control of protein preparations and for the validation of hits and identification of false-positives from screening campaigns.[2] Furthermore, biophysical parameters like thermodynamic signatures, residence times and binding mechanisms emerged to complement traditional parameters as the activity towards the target, the drug-likeness and lead-likeness to develop a rational basis for the selection of promising candidates for further optimization.[1,3–7] Especially, methods like X-ray crystallography, nuclear magnetic resonance spectroscopy (NMR), isothermal titration calorimetry and binding assays allow insights into the structure, molecular mechanism, thermodynamics and kinetics of the binding reaction.[1,2,8]   Not surprisingly, the first biophysical methods which were integrated into drug discovery processes were structure based methods like X-ray crystallography and NMR spectroscopy as they allowed a detailed molecular view of protein-ligand interactions.[1,8,9] An advantage of these methods is the reliable identification of unique structural elements like subpockets, which can be exploited to generate selective ligands and in combination with computational methods they evolved to be the basis for structure based drug design approaches. Today, these methods are also successfully implemented into screening procedures, especially for fragment based drug design. As for most methods, structural techniques are more powerful if they are combined with other methods like binding and activity assays to obtain information about the affinity of the interaction.[8]             Binding constants and thermodynamic signatures A classical parameter to describe the activity of compounds towards a target is the determination of IC50- and EC50-values, which reflect the compound concentration at which the inhibition (IC50) or more general the effect (EC50) is half maximal. As these values are dependent on the used test parameters and are especially sensitive to the concentrations of the reactants, the equilibrium dissociation constant, Kd, of the protein-compound complex is a more reliable parameter to compare different compounds. This value defines how willingly the protein-compound complex dissociates and the lower a Kd-value of a molecular interaction is the higher is the affinity. Physically, the Kd-value of a molecular interaction depends on the change of the Gibbs energy at standard conditions (ΔG0), which denotes the difference between the energy of the complex and the energy of the free binding partners and defines 
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the distribution between the bound and unbound state at equilibrium conditions. The change of the Gibbs energy is furthermore composed of enthalpic (ΔH0) and entropic (ΔS0) contributions to binding and as for the Kd-value it applies the lower (more negative) the value for ΔG0 is the higher is the affinity.  
∆
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=  ×  × ln
 = ∆

−  × ∆
     (1) with R = universal gas constant, T = thermodynamic temperature Optimizing the change in Gibbs energy upon complex formation towards more negative values results consequently in a lower Kd-value and an increased affinity towards the target. This approach has been highlighted by Bissantz et al. as the only reasonable way for optimizing compounds as other approaches are very dependent on the system under investigation.[10] Furthermore, Kd-values are easily determined and the most useful parameter to establish structure-activity relationships.  Improvements in the Kd-value are often achieved by the addition of hydrophobic moieties like methyl or ethyl groups to the ligand.[7,11] According to Ladbury et al. this approach has serious drawbacks since the gain in affinity through hydrophobic moieties mostly results from greater entropic contributions, which are believed to negatively impact the selectivity of the ligand.[11] In general, entropic contributions to binding result from a change in the degree of freedom of the system upon binding.[12,13] While unfavorable entropic contributions result mainly from a fixation of the ligand and from a structuring or decreased flexibility of the target-ligand complex, favorable contributions are gained through the release of structured water clusters from the binding pocket and a desolvation of hydrophobic moieties of the ligand or target molecule.[12–14] These effects are often observed for hydrophobic interactions and therefore also referred to as hydrophobic effect.  Favorable enthalpic contributions to binding result from polar interactions like hydrogen bonding and chelation of metal ions but also from van-der-Waals interactions and an optimal geometric fit of the ligand into the binding pocket.[11,13,14] According to Ladbury et al. and Freire et al. favorable enthalpic contributions are more specific since the geometry of the binding site and the possible positions of hydrogen bonds are dependent on the target.[15] On the other hand the optimization of the enthalpic contributions is extraordinary hard, especially without structural information of the target as these types of interactions follow strict geometric rules and the distances and angles of the interacting groups have to be accurately adjusted.[11,16] Polar groups which are wrongly positioned have are large negative effect on the binding enthalpy if they are desolvated upon binding but not able to reestablish a polar interaction in the bound state. Furthermore, it is often observed that generated favorable enthalpic contributions are compensated by unfavorable entropic contributions due to a decrease in the degree of freedom caused by a strong fixation of the ligand and/or the binding pocket.[12,13,16] In order to overcome these difficulties Ladbury et al. and Freire et al. suggest to include a thermodynamic characterization of the binding reaction in early stages of drug development 
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processes and to select leads for further optimization, which already possess favorable enthalpic contributions.[11,13,17] On the other hand the thermodynamics of protein-ligand interactions are very complex and the value of enthalpy based ligand optimization without knowing about the molecular or structural basis is questionable.[16,18]   Binding kinetics and residence time Another aspect which has to be considered for the selection of lead structures is their behavior in non-equilibrium systems like the human body. Equilibrium data as Kd-values and thermodynamic signatures are not suitable to predict the time dependency of the binding degree but since a compound is only active while it is bound to its target, this information is crucial.[19] The behavior of a compound at dynamic conditions is defined by its kinetic rate constants and compounds with similar affinities can exhibit large differences in their binding kinetics. In certain circumstances unfavorable kinetic rate constants could hamper the activity in vivo although the ligand exhibits a high affinity in vitro.[20] Optimization of the binding kinetics is therefore an important task during compound development.[21–23]   Copeland and Tummino started to tackle this task with the introduction of the "residence time concept" which focuses on the optimization of the dissociation rate of a compound.[19,24] Slower dissociation rates are thereby believed to result in an increased target occupancy after most of the unbound ligand has been washed out. In the best case this would allow to increase the intervals between the application of the compound, which could reduce unwanted side effects through a temporal discrimination to unspecific binding.[24,25] Focusing on dissociation rates results often in a negligence of the association rates but computational simulations indicate that also a high affinity binder has to possess a considerable association rate to exhibit a effect in vivo at therapeutic relevant concentrations. [20] Furthermore, besides its binding kinetics the in vivo effect of a compound is also dependent on its pharmacokinetics and it was elucidated that in several cases the plasma half life is indeed the rate limiting step.[20] Taken together these findings suggest that the binding kinetics of a compound should be balanced in order to achieve a high efficacy in vivo.[26]   Binding mechanisms Besides association and dissociation rates, kinetic studies of a binding reaction are useful to gain insights into the molecular binding mechanism. On the one hand mechanistic studies help to understand the molecular basics of the binding reaction but furthermore they can be used to stratify ligands and to identify compounds with unique mechanistic characteristics, which can serve as good 
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starting points for the development of selective and save compounds with an optimized therapeutic index.[27]     The simplest kinetic model to describe a binding reaction is a one step association and dissociation mechanism. Thereby, the complex formation is determined by a single exponential kinetic and at pseudo first order conditions the observed rate constants, kobs, possess a linear dependency on the concentration of the varied binding partner. From the slope and the y axis intercept it is possible to determine the association rate constant, kon and the dissociation rate constant, koff.[24]  In practice, binding reaction often occur with more complex mechanisms which involve several unimolecular isomerization steps. Two prominent models which have been proposed are the induced fit model and the conformational selection model (Figure 1). The induced fit model was introduced in 1958 by Koshland and it describes a two step binding reaction, where the initial ligand-protein complex isomerizes unimolecular into a thermodynamically more stable complex.[28] In contrast the conformational selection mechanism assumes that the protein exists in at least two different conformations of which one is accessible to the binding reaction.[29–31] Besides these simple models several combinations and extensions of both mechanisms can be formulated to describe more complex binding reactions. For the discrimination between these more complex models determining the concentration dependence of the observed rate constants is not sufficient and other parameters have to be integrated into a global fit approach.[32] Although, a controversial debate about the generalization of both formalisms is present in the literature, experimental data indeed indicates that both mechanisms occur.[29,33–35] The conformational selection approach has been recently used for the development of allosteric kinase inhibitors, which lock the protein in an inactive conformation.[36] Induced fit mechanisms were formulated especially for the binding into dynamic subpockets and for the enclosure of ligand between flexible loop regions.[22,37]    
+ +k1k-1 k2k-2k1k-1+ k1k-1 k2k-2Figure 1: Schematic representation of an one step (top), a conformational selection (middle) and an induced fit (bottom) binding reaction. 
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2.2. Human histone deacetylases  The acetylation of the ε-amino function of lysine residues is an often observed post-translational modification of proteins. First described by Phillips and Allfrey et al. in 1963/64 the subsequent research focused mainly on histones and other epigenetically relevant proteins.[38–41] But during the last 20 years and especially with the arise of proteomic methods it appeared that proteins of many cell physiological areas can be acetylated and that this modification seems as abundant as phosphorylations.[42–45] Interestingly, more recent studies indicate that protein acetylation also frequently occurs in bacteria like Escherichia coli, Salmonella enterica and Pseudomonas aeruginosa, which is in contrast to the general assumption that simpler life-forms are mostly not capable of post-translational protein modifications.[42,46–51] The acetylation of lysine residues itself is catalyzed by histone acetyltransferases (HATs), whereas the deacetylation is catalyzed by histone deacetylases (HDACs).   Based on their sequence phylogeny the 18 isotypes of the human HDACs are divided into four classes. The classes I (HDAC1, 2, 3 and 8), II (IIa: HDAC4, 5, 7 and 9; IIb: HDAC6 and 10) and IV (HDAC11) are Zn2+dependent in contrast class III HDACs (SIRT 1–7) require NAD+ as a cofactor.[52] For class I, IIb and IV HDACs the active site is highly conserved and consists of two lateral histidines and a tyrosine, that are located at the bottom of the active site pocket next to the catalytic Zn2+ ion, which is coordinated by two aspartic acids and a further histidine.[53–54] In class IIa HDACs the tyrosine is replaced by a histidine, which turns these proteins essentially inactive towards acetylated substrates. The catalytic activity can be restored by replacement of the histidine by tyrosine.[55] The two histidines have also be found to be crucial for the deacetylation mechanism as indicated by site directed mutagenesis studies with HDAC8 and bacterial HDAC homologues.[56–59] Both histidines form charge relay systems through hydrogen bonding with aspertate residues and this is believed to affect the pKa of the histidines.[59,60,61] Besides the active site the secondary and tertiary structures of the deacetylase domains are highly conserved as well. The core consists of eight parallel beta strands, which are surrounded by alpha helices and disordered loop regions (Figure 2). The catalytic zinc ion is located at the bottom of a pocket, which is connected to the protein surface through a narrow channel and the entrance is formed by six loops. Furthermore, the deacetylase domain exhibits two binding sites for monovalent cations like potassium or sodium ions, which are able to influence the deacetylase activity.[56] 
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 Figure 2: (top panel) General structure of Zn2+ dependent histone deacetylases based on the crystal structure of HDAC8 (3F07). Beta sheets are colored in blue, alpha helices in teal and loops in grey. The magenta sphere represents the catalytic zinc ion whereas the structural potassium ions are colored in purple. (bottom, left) Cut-open view of the surface of the active site pocket. (bottom, right) Close up view of the active site of HDAC8.  Based on the crystal structure of a histone decatylase like protein (HDLP) from Aquifex aeolicus the first detailed reaction mechanism was proposed by Finnin and colleagues.[53] They suggested a general acid-base catalytic pair mechanism, where the histidine corresponding to H143 in HDAC8 is protonated and the histidine corresponding to H142 in HDAC8 acts as a base and abstracts a proton from the reactive zinc bound water. The proton of the H143 corresponding histidine acts as an acid and is used to facilitate the second amide bond cleavage.[53]  Vanommeslaeghe et al. suggested a different mechanism, which was based on computational methods and the crystal structure of HDLP.[61] They proposed that the H142 corresponding histidine deprotonates a water molecule resulting in a protonated histidine and a hydroxide ion, which is bound between the zinc ion and the tyrosine. During the deacetylation the proton of the H142 corresponding histidine is transferred to the H143 corresponding histidine and used further to facilitate the second amide bond cleavage.[61] As a third mechanism a proton-shuttle mechanism was formulated by Zhang and colleagues based on computational methods and crystal structures of HDLP and HDAC8.[60,62] The authors suggested that both histidines are in a non-protonated state upon substrate binding and that the H143 corresponding histidine acts as a base as well as an acid catalyst during the deacetylation. Although this mechanism was initially contested by Chen et al. the key role of the H143 corresponding histidine is supported by 
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a recently published experimental study with HDAC8, which proposed a single residue acid-base catalysis for the H143 corresponding histidine as well.[59,63] But also the mechanism proposed by Finnin and colleagues got recent support by a comprehensive crystallographic study with HDAC6 indicating that indeed both mechanisms occur (Figure 3).[64]    
 Figure 3: (top) General acid-base catalytic pair mechanism as proposed by Finnin and colleagues. (bottom) Proton-shuttle or single residue acid-base mechanism as proposed by Fierke and coworkers. Numbering of the amino acids is based on HDAC8.   Although, the general organization of the deacetylase domains is highly conserved among the human HDACs, small differences especially in the loops regions can be observed, which effects the function and regulation of the isotypes.[65,66] Class I HDACs are homologous to the yeast HDAC Rpd3, ubiquitously expressed and are mainly localized in the nucleus of the cell.[52] They are mostly recognized for their ability to control the gene expression epigenetically by deacetylation of acetylated histones.[54] But during the last decade also a number of non-histone proteins like p53, ERRα and CREB have been found to be substrates of class I HDACs.[67–70] While HDAC8 is solely active, HDAC1–3 are recruited to large multi protein complexes for their function and possess a longer C-terminal tail.[70–73] Recently, the structure of HDAC3 in complex with the deacetylase activating domain (DAD) of the nuclear receptor corepressor 2 (N-CoR2) has been solved.[74] Unexpectedly, the authors found inositol 1,4,5,6-tetrakisphosphate (Ins(1,4,5,6)P4) to be bound in a basic pocket between both proteins and further studies indeed indicated that Ins(1,4,5,6)P4 is needed for the activation of HDAC3 (Figure 4).[74,75] A multiple sequence alignment revealed that the amino acids responsible for the binding of Ins(1,4,5,6)P4 are conserved among HDAC1, 2 and 3 but are absent in HDAC8.[74] Furthermore, a second multiple sequence alignment indicated that the Ins(1,4,5,6)P4 binding amino acids of the DAD are conserved among other HDAC activating proteins like the REST corepressors 1–3, the nuclear receptor corepressor 1 and the metastasis-associated proteins MTA1–3. 
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Figure 5: Overlay of the deacetylase domain of HDAC4 in the open (teal, 2VQJ) and closed (grey, 5A2S) state. The catalytic zinc ion is indicated as magenta sphere, whereas the structural zinc ion is colored in purple.   
Elucidation of the structure of the HDAC1:MTA1 complex revealed indeed a similar binding pocket for Ins(1,4,5,6)P4 and a similar activation behavior was observed as for the HDAC3:DAD complex.[75,76]   Figure 4: (left) Structure of the HDAC3(teal):DAD(grey) complex (4A69) bound to Ins(1,4,5,6)P4 (red). The catalytic zinc ion is represented by the magenta sphere and the structural potassium ions are colored in purple. (right) Close up view of the inositolphosphate binding site of the HDAC3:DAD complex.      HDACs of the class II are subdivided into class IIa and class IIb and are homologous to the yeast HDAC Hda1.[77,78] While HDAC10 is mostly localized in the nucleus, HDAC6 is a mainly cytosolic protein and it is also the only HDAC with two active deacetylase domains.[64,78–80] Prominent substrates are α-tubulin, HSP90 and cortactin, through which HDAC6 influences cell migration and angiogenesis.[81–83] Furthermore, HDAC6 is required for the binding and transport of protein aggregates as it possesses a ubiquitin binding domain which binds to unanchored ubiquitin of protein aggregates.[84] HDACs of the class IIa exhibit a large N-terminal domain through which they interact with transcription factors like RelB and the myocyte enhancer factors 2 A–D.[78,85–90] They are tissue dependently expressed and shuttle between the cytoplasm and the nucleus in a highly regulated way.[85,91–93] As aforementioned class IIa HDACs are inactive towards classic HDAC substrates through a tyrosine to histidine exchange in the active site but they are able to recruit class I HDAC containing multi protein complexes.[55,85,94,95] The main differences to other HDACs are localized in the L1 and L2 loops as crystal structures revealed a second zinc binding site. This structural zinc is either bound between two histidines and two cysteines resulting in an open protein conformation or between one histidine and three cysteines, which results in a closed conformation (Figure 5).[55] For HDAC4 it was observed that two of the zinc binding cysteines can form a intramolecular disulfide bond 
 Introduction  15 Figure 6: Structure of HDLP (top, 1C3S), APAH from Mycoplana ramosa (middle, 3Q9B) and HDAHpa (bottom, 5G10). The loops (L2 (green) for APAH, L1 (green) for HDAHpa and for comparison L1 (green) and L2 (grey) for HDLP) responsible for dimerization and tetramerization are highlighted. The catalytic zinc ion is indicated as magenta sphere.  
in response to reactive oxygen species, which induces a shuttling of HDAC4 from the nucleus to the cytoplasm. The disulfide bond can be reduced by thioredoxin 1.[96] Interestingly, studies of the interaction between HDAC4 and N-CoR2 revealed that the structural zinc binding site is very important for the binding reaction and furthermore, it was shown that the binding depends on conserved motifs, which are unique for N-CoR1 and N-CoR2.[94,95]   2.3. Prokaryotic histone deacetylase-like amidohydrolases  Most so far identified prokaryotic proteins of the histone deacetylase family are acetylpolyamine deacetylases (APAHs), acetoin utilization proteins, histone deacetylase-like proteins (HDLPs), histone deacetylase-like amidohydrolases (HDAHs) and sirtuin homologue deacetylases.[53,97–100] In general, APAHs catalyze the deacetylation of acetylated polyamines and acetoin utilization proteins are part of the acetoin metabolism.[97] Proven APAHs were for example identified for Mycoplana ramosa and Pseudomonas aeruginosa.[100,101] Although, the exact functions and substrates of HDLPs and HDAHs are not known yet, preliminary results indicate that they act on acetylated proteins rather than on acetylated polyamines.[53,58,99] For instance, it has been shown that the HDAC6 homologous HDAH from Pseudomonas aeruginosa (HDAHpa) is indeed unable to deacetylate polyamines in vitro.[58] Another HDAC6 homologous HDAH from Bordetella/Alcaligenes (HDAHbo) is able to catalyze polyamine deacetylation, but the determined activity is relatively low compared to proven APAHs from Mycoplana ramosa and Pseudomonas aeruginosa.[99–101] Furthermore, HDAHbo was found to be inhibited by known HDAC inhibitors and to be active on acetylated histones and synthetic HDAC substrates.[99] Therefore, HDAHs and HDLP have been used as model system for human 
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HDACs. HDAHbo was used for the development of binding assays and HDLP from Aquifex aeolicus, which is homologue to HDAC1 was the first crystallized HDAC isotype and served as template for the elucidation of the molecular mechanisms of inhibition and catalysis of HDACs.[53,102–105] The determined secondary and tertiary structure of HDLP exhibits the same open α/β folds, which were later found to be conserved among the Zn2+ dependent HDACs (Figure 6).[66] The same core structure was also determined for the APAH from Mycoplana ramosa and for HDAHbo and HDAHpa.[58,100,102] Interestingly, HDAHs as well as APAHs exhibit an elongated loop compared to HDLP and other class I and IIb HDACs, which impacts the quaternary structure(Figure 6). APAHs form a "head-to-head" dimer through an elongated L2 loop.[100] In contrast, HDAHs possess an elongated L1 loop which causes not only a "head-to-head" dimerization but furthermore a tertamerization occurs as a dimer of two dimers is formed.[58] For APAHs as well as for HDAHs the dimerization alters the entrance and the shape of the active site, which is believed to affect the specificity of substrate and inhibitor recognition (Figure 7).[58,100]    Figure 7: Surface representation of the entrance (top panel) and shape (bottom panel) of the active site of HDLP bound to SAHA (left, 1C3S), APAH dimer from Mycoplana ramosa bound to M344 (middle, 3Q9B) and HDAHpa dimer bound to SATFMK (right, 5G10). The catalytic zinc ion is indicated as magenta sphere.       
 Introduction  17 
2.4. Biophysics for inhibitors binding to histone deacetylases  Through their important functions in the epigenetic regulation of gene expression human HDACs have been identified as protein targets for the treatment of different types of cancer.[106–109] Four HDAC inhibitors have been approved by the United States Food and Drug Administration between 2006 and 2015 for the treatment of cutaneous and peripheral T-cell lymphoma and multiple myeloma and several more are in clinical trials (Figure 8).[110] Besides cancer HDAC are evaluated as targets for a broad range of different disorders ranging from neurodegenerative diseases like Parkinson's disease and Huntington's chorea over diabetes type 2 and disadvantages resulting from physical inactivity to parasitic infections.[109,111–117] While unwanted side effects of HDAC inhibitors like fatigue, nausea and thrombocytopenia are more or less tolerated for the treatment of cancer, they have to be reduced for other therapeutic approaches, especially if nonhuman HDACs are targeted.[108,118] Three of the four approved HDAC inhibitors SAHA, PXD101, LBH589 and FK228 exhibit a characteristic structure which consists of a zinc binding group, an aliphatic spacer and a capping group which is connected to the spacer through a polar connection unit. They were found to be rather unselective and huge efforts are undertaken to develop better and isotype selective HDAC inhibitors in order to reduce unwanted side effects.[119]   As stated above the biophysical characterization of protein-ligand interactions is a valuable tool for the identification and selection of selective ligands. For HDACs and HDAC-like proteins especially crystallographic studies were carried out and indeed all Zn2+ dependent human HDACs except for HDAC5, 9, 10 and 11 have been crystallized.[119,120] Based on the structure of the class I homologue HDLP it was possible to develop a HDAC1/2 selective ligand. Therefore, the aminophenyl moiety of the known HDAC1, 2, 3 and 11 selective Inhibitor MS-275 was extended with a thienyl moiety to occupy the larger foot pocket.[121,122] The resulting ligand inhibits HDAC1 and 2 with IC50-values of 20 and 100 nM and is inactive against HDAC3 up to concentrations of 20 µM.[122] This concept was also applied by Bressi et al., Lauffer et al. and Wagner et al. who crystallized HDAC2 in complex with different N-(2-aminophenyl)-benzamide based inhibitors (Figure 9).[123–125] Bressi et al. explored the foot pocket in more detail and found a strong preference for phenyl, 4-fluorophenyl and 2- or 3-furanyl extensions, which inhibit HDAC2 with IC50-values between 27 and 43 nM. Furthermore, they 
HN O NHO OHHN NH HNO OH
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Figure 8: Approved cancer drugs. 
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elucidated that inhibitors with a N-(2-aminophenyl)-benzamide based scaffold are slow and tight-binding inhibitors since the IC50-values decrease up to 42-fold upon longer incubation times.[125] The slow binding characteristics of benzamide based inhibitors were further exploited by Wagner et al. to achieve a temporal discrimination between HDAC1 and 2.[123] Especially, the developed compounds BRD4884 and BRD6688 possess useful kinetic profiles. BRD4884 allows a specific engagement of HDAC1 as the slow association rate for HDAC2 prevents an effective binding at dynamic conditions. In contrast, the compound BRD6688 exhibits a six times longer residence time for HDAC2 compared to HDAC1 which results in a longer lasting inhibition of HDAC2.[123] Kinetic and structural insights into the binding of MS-275, SAHA, Trichostatin A (TSA) and two extended N-(2-aminophenyl)-benzamide based inhibitors to HDAC1 and 2 were also provided by Lauffer et al. who performed kinetic studies to determine association rate constant and the residence time using a reporter displacement assay developed by Neumann and colleagues.[124,126] Unfortunately, the detailed assay principles and the chemical structure of the used probe are not published. For TSA and SAHA the binding kinetics were found to be fast. In contrast MS-275 and the extended benzamide based compounds were found to be slow binders with similar association rates between 1.44x102 and 4.4x102 M-1s-1. The extended benzamide based compounds exhibit slower dissociation rates than MS-275 resulting in an increased affinity and residence times in the order of 20–38 hours. Furthermore, they crystallized HDAC2 in complex with the hydroxamic acid SAHA and a benzamide based compound. The crystal structures revealed that the pocket responsible for the incorporation of the extended benzamide scaffold is opened upon ligand binding through a rotation of leucine 144 (Figure 10).[124] 
Figure 9: N-(2-aminophenyl)-benzamide based HDAC inhibitors. 
N O HNO NHO NH2 F NHNH2OO N NH2NHONHN O HNO NH2 NN OHN FH2NMS-275 BRD4884 BRD6688pimelic diphenylamide 106 RGFP966
 Introduction  19 
   Figure 10: Surface representation of the active site of HDAC2 bound to a N-(2-aminophenyl)-benzamide based inhibitor (left, 4LY1) and SAHA (right, 4LXZ). The catalytic zinc ion is represented by the magenta sphere. Leucine 144 which undergoes a conformational switch upon binding of the N-(2-aminophenyl)-benzamide based inhibitor is highlighted in green.       The authors of the conducted kinetic studies assumed a one step binding reaction for the inhibition of HDAC1 and 2 and indeed a mechanistic study with the related compound pimelic diphenylamide 106 revealed a one step binding mechanism for HDAC1 and 2.[127] Interestingly, the authors found that binding of this compound to HDAC3 occurs with a two step induced fit mechanism. Furthermore, the determined inhibition constants revealed an about ten times stronger binding to HDAC3 compared to HDAC1.[127] The scaffold of this inhibitor was therefore used to design the HDAC3 selective ligand RGFP966 which inhibits HDAC3 with an IC50-value of 80 nM and shows a 200-fold selectivity over other HDAC isotypes (Figure 9).[128]     As described above the structure of the foot pocket of class I HDACs 1, 2 and 3 is crucial for the observed selectivity of N-(2-aminophenyl)-benzamide based inhibitors. For HDAC8 this pocket is partially occupied as the leucine, which is responsible for the opening of the foot pocket is exchanged by a tryptophane.[124,129,130] The resulting differences in the structure of the foot pocket were exploited by Whitehead et al. to generate HDAC8 selective ligands with a (R)-α-amino-ketone moiety. The two developed compounds 1 and 2 inhibit HDAC8 with IC50-values of 0.09 and 0.2 µM and achieved a 18- to 150-fold selectivity over HDAC1, 2 and 6. Especially, the high selectivity of the less affine binder 2 is comparable to the gold standard PCI-34051, which inhibits HDAC8 with an IC50-value of 10 nM and exhibits a 200-fold selectivity over other HDAC isotypes (Figure 11).[130,131]  Besides the structure based design, HDAC8 was also used to investigate the thermodynamics, kinetics and the mechanism of the binding of selected compounds. The research group of Srivastava elucidated the kinetic binding mechanism and the thermodynamics for the binding of SAHA and TSA.[132] For 
O N HNO OH FF O N N O NH2 ClPCI-34051 N OH2N ClCl12Figure 11: HDAC8 selective inhibitors 
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the determination of the kinetic properties it was exploited that binding of both compounds results in a binding specific quenching of the intrinsic tryptophane fluorescence. Using stopped-flow experiments it was determined that binding of both compounds to HDAC8 occurs in fast binding reactions via a two step induced fit mechanism. The thermodynamic characterization by isothermal titration calorimetry of the binding reactions revealed higher enthalpic contributions for the binding of SAHA than for binding of TSA. The authors postulated that these result from an additional hydrogen bond and concluded that SAHA establishes overall more specific interactions.[132] The determined binding enthalpies were corrected in a second study as it was elucidated that protonation effects had to be included into the analysis. By performing isothermal titration calorimetry experiments in different buffers it was determined that binding of TSA and SAHA is mainly entropy driven.[133]          Quite similar to the binding of SAHA and TSA to HDAC8 the binding of (E)-3-(Furan-2-yl)-N-hydroxyacrylamide (FAHA) to HDAHbo results in a reduced intrinsic tryptophane fluorescence.[103] By performing stopped-flow experiments the research group of Meyer-Almes elucidated an induced fit mechanism for the binding reaction, but in contrast to HDAC8 the reaction requires three steps.[134] The authors proposed that the initial binding of FAHA occurs at that the surface of HDAHbo in a rapid equilibrium. From there the inhibitor relocates to the active site and a second transient complex is formed, which finally isomerizes into a more stable complex.[134] The strong quenching properties of FAHA were further exploited to develop a reporter displacement assay, which was used to determine the binding constants of unlabeled inhibitors.[103] Another reporter displacement assay, that was developed by the same group was based on hydroxamic acid probes, which were conjugated to a dansyl moiety.[104] Upon binding of the dansyl conjugates a Förster resonance energy transfer between the intrinsic tryptophanes of HDAHbo and the dansyl moiety occurred and was exploited to determine the binding degree of the probes and the respective binding constants of the probes and of unlabeled compounds. Furthermore, the thermodynamic signatures of the probes and unlabeled compounds were determined by investigating the temperature dependence of the binding constants. Interestingly, it was found that higher enthalpic contributions to the binding resulted in an increased selectivity against HDAC1.[104]   Most biophysical studies on HDACs have been performed with isolated proteins, but as the function of several human HDACs is dependent on the binding to other proteins the influence of these interactions has to be considered for the development of selective ligands.[135] Bantscheff et al. started to evaluate the influence of complex formation on the affinity of selected ligands by a mass spectrometry based approach.[136] They elucidated that two ligands exhibited indeed a preference for HDAC3 containing complexes while being inactive towards HDAC1/2 containing SIN3 complexes.[136] One parameter, 
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that is likely affected by the binding to other proteins is the flexibility of the binding pocket as indicated by computational simulations for HDAC3, which propose a structural stabilization of the loops surrounding the active site by binding of the DAD.[137,138] Besides HDAC3, changes in the structural changes upon complex formation are also proposed for class IIa HDACs, since they are able to switch between an open and a closed state.[55] The closed state is thereby believed to be the active conformation, which is accessible to protein-protein interactions. Bottomley et al. developed the ligand 3, that locks HDAC4 in the open state and successfully inhibits complex formation with the N-CoR:HDAC3 complex (Figure 12).[55] The applicability of this approach was also demonstrated by Issacs et al. who identified tasquinimod as an allosteric inhibitor of HDAC4 which binds with a Kd-value of 10–30 nM and prohibits binding to N-CoR2.[139] The authors proposed that binding of tasquinimod occurs in proximity to the structural zinc binding domian and locks HDAC4 in the open state.[139] Besides the open state, also the closed state of class IIa HDACs can be targeted to develop class selective ligands. Dominguez et al. used therefore the crystal structure of HDAC4 to design and optimize ligands based on the structure of  4 developed by Tessier and colleagues.[140-142] Interestingly, they used a cyclopropane core to achieve a geometrical preforming of the ligand. This strategy allowed to develop ligands like 5, which inhibit class IIa HDACs with IC50-values in the two digit nanomolar range and exhibit at least 28-fold selectivity over other HDAC isotypes.[142] Another class IIa selective ligand was identified by Lobera et al. by a high throughput screening with HDAC9.[143] The determined inhibitory constants for the hit compound TMP-269 for class IIa HDACs were 19 and 126 nM, resulting in an at least 18-fold selectivity over other HDAC isotypes. TMP-269 possesses a trifluoromethyloxadiazole moiety, which was found to be a nonchelating zinc binding group.[143]   2.5. Objectives of the work  Human HDACs have emerged to be proven protein targets for the treatment of cancer and are evaluated as targets for a broad range of other diseases.[110,113,144] With SAHA, PXD101, LBH589 and FK228 four compounds were approved by the United States Food and Drug Administration for the treatment of different types of cancers.[145] They cause severe side effects like fatigue, nausea, anemia thrombocytopenia and leukopenia and most of these compounds were found to be pan 
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inhibitors.[108,118] Although several strategies were exploited for the development of selective inhibitors and indeed some success is visible, most compounds are if at all only class selective.[119,120] Furthermore, most compounds are from a narrow chemical space and are based on the traditional design concept. Several investigated compounds and also three of the approved drugs are hydroxamic acids which has serious drawbacks for the application of these compounds for not life threatening diseases since hydromxamic acids were found to be potentially mutagenic and are prone to unspecific reactions with other metal-dependent proteins.[143,146] For the identification of novel HDAC inhibitors with other chemical entities high throughput screening of diverse compound libraries would be useful. A necessary condition for conducting a high throughput campaign is the availability of suitable assays. For HDACs, most assays are activity based and require the deacetylation of a synthetic peptide.[147] The deacetylated peptide is then converted into a fluorescent product by the addition of trypsin and luciferase if a luminogenic assay is conducted.[148-150] Although these assays have been applied for screening they have some drawbacks as multi enzyme reactions and activity based assays are prone to errors which might result in a high false-positive rate.[143,151,152] Other approaches used labeled inhibitors as probes for the development of binding assays to determine binding constants, which are better suited than IC50-values for the establishment of structure-activity relationships. Simultaneously, Riester et al. and Mazitschek et al. developed a binding assay for HDACs by fusing a fluorescent moiety to an unselective HDAC inhibitor.[105,153] Mazitschek et al. monitored the binding of HDACs via changes in the fluorescence polarization of the probe.[153] The assay developed by Riester et al. was able to use changes in the fluorescence anisotropy as well as in the fluorescence life-time of the probe as a readout resulting in a dual parameter assay, which was well suited for screening applications.[105,152]  Following up on their work, one part of this work is focused on the expansion of the methodology for the screening for HDAC inhibitors and the determination of their binding constants. Therefore, suitable binding assays are developed and evaluated for their applicability for high throughput screening. In order to reduce the false-positive rate and the subsequent efforts for compound logistics and retesting  the robust readout fluorescence life-time is chosen. To facilitate the drug discovery process for novel HDAC inhibitors further, the second part of this work evaluates whether a biophysical characterization of HDAC inhibitors can be used to estimate the selectivity of HDAC inhibitors. Since biophysical binding characteristics, like thermodynamic signatures, binding kinetics and mechanisms were successfully applied for other systems and used to develop a rational approach for the selection of promising lead structures, these parameters are determined and evaluated for their impact on the selectivity. For this propose closely to human HDACs related bacterial HDAHs are used as model systems. To gain further insights into the binding reaction the influence of the accessibility and flexibility on the thermodynamics are evaluated and it is 
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investigated how the thermodynamics, kinetics and mechanisms of the binding of HDAC inhibitors can be combined to identify and stratify selective compounds.     
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4.1. Fluorescence life-time based binding assay for histone deacetylases  Title: A fluorescence lifetime-based binding assay for acetylpolyamine amidohydrolases from  Pseudomonas aeruginosa using a [1,3]dioxolo[4,5-f]benzodioxole (DBD) ligand probe.  Authors: Christian Meyners, Robert Wawrzinek, Andreas Krämer, Steffen Hinz, Pablo Wessig, Franz-Josef Meyer-Almes   Bibliographic Data: Analytical and Bioanalytical Chemistry Volume 406, Issue 20, Pages 4889–4897, August, 2014. DOI: 10.1007/s00216-014-7886-5 First published online: May 29, 2014  Abstract: High-throughput assays for drug screening applications have to fulfill particular specifications. Besides the capability to identify even compounds with low potency, one of the major issues is to minimize the number of false-positive hits in a screening campaign in order to reduce the logistic effort for the subsequent cherry picking and confirmation procedure. In this respect, fluorescence lifetime (FLT) appears as an ideal readout parameter that is supposed to be robust against autofluorescent and light-absorbing compounds, the most common source of systematic false positives. The extraordinary fluorescence features of the recently discovered [1,3]dioxolo[4,5-f][1,3] benzodioxole dyes were exploited to develop an FLT-based binding assay with exceptionally robust readout. The assay setup was comprehensively validated and shown to comply not only with all requirements for a powerful high-throughput screening assay but also to be suitable to determine accurate binding constants for inhibitors against enzymes of the histone deacetylase family. Using the described binding assay, the first inhibitors against three members of this enzyme family from Pseudomonas aeruginosa were identified. The compounds were characterized in terms of potency and selectivity profile. The novel ligand probe should also be applicable to other homologues of the histone deacetylase family that are inhibited by N-hydroxy-N′-phenyloctandiamide.  Contributions by C. Meyners: 
• Developed and executed the fluorescence lifetime binding assay 
• Analyzed the generated data 
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Title:  A fluorescence lifetime-based binding assay for class IIa histone deacetylases.  Authors: Christian Meyners, Monique Mertens, Pablo Wessig, Franz-Josef Meyer-Almes  Bibliographic Data: Chemistry – A European Journal Volume 23, Issue 13, Pages 3107–3116, March 2, 2017. DOI: 10.1002/chem.201605140 First published online: December 6, 2016  Abstract: Class IIa histone deacetylases (HDACs) show extremely low enzymatic activity and no commonly accepted endogenous substrate is known today. Increasing evidence suggests that these enzymes exert their effect rather through molecular recognition of acetylated proteins and recruiting other proteins like HDAC3 to the desired target location. Accordingly, class IIa HDACs like bromodomains have been suggested to act as “Readers” of acetyl marks, whereas enzymatically active HDACs of class I or IIb are called “Erasers” to highlight their capability to remove acetyl groups from acetylated histones or other proteins. Small-molecule ligands of class IIa histone deacetylases (HDACs) have gained tremendous attention during the last decade and have been suggested as pharmaceutical targets in several indication areas such as cancer, Huntington's disease and muscular atrophy. Up to now, only enzyme activity assays with artificial chemically activated trifluoroacetylated substrates are in use for the identification and characterization of new active compounds against class IIa HDACs. Here, we describe the first binding assay for this class of HDAC enzymes that involves a simple mix-and-measure procedure and an extraordinarily robust fluorescence lifetime readout based on [1,3]dioxolo[4,5-f]benzodioxole-based ligand probes. The principle of the assay is generic and can also be transferred to class I HDAC8.   Contributions by C. Meyners: 
• Produced the used proteins 
• Developed and executed the fluorescence lifetime binding assay 
• Performed the ITC measurements 
• Analyzed the generated data 
• Wrote the manuscript 
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4.2. Determining the kinetic binding mechanism of histone deacetylase inhibitors  Title: Kinetic method for the large-scale analysis of the binding mechanism of histone deacetylase inhibitors.  Authors: Christian Meyners, Matthias G. J. Baud, Matthew J. Fuchter, Franz-Josef Meyer-Almes  Bibliographic Data: Analytical Biochemistry Volume 460, Pages 39–46, September 1, 2014. DOI: 10.1016/j.ab.2014.05.014 First published online: June 2, 2014  Abstract: Performing kinetic studies on protein ligand interactions provides important information on complex formation and dissociation. Beside kinetic parameters such as association rates and residence times, kinetic experiments also reveal insights into reaction mechanisms. Exploiting intrinsic tryptophan fluorescence a parallelized high-throughput Förster resonance energy transfer (FRET)-based reporter displacement assay with very low protein consumption was developed to enable the large-scale kinetic characterization of the binding of ligands to recombinant human histone deacetylases (HDACs) and a bacterial histone deacetylase-like amidohydrolase (HDAH) from Bordetella/Alcaligenes. For the binding of trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), and two other SAHA derivatives to HDAH, two different modes of action, simple one-step binding and a two-step mechanism comprising initial binding and induced fit, were verified. In contrast to HDAH, all compounds bound to human HDAC1, HDAC6, and HDAC8 through a two-step mechanism. A quantitative view on the inhibitor-HDAC systems revealed two types of interaction, fast binding and slow dissociation. We provide arguments for the thesis that the relationship between quantitative kinetic and mechanistic information and chemical structures of compounds will serve as a valuable tool for drug optimization.   Contributions by C. Meyners: 
• Produced the used proteins 
• Developed and executed the kinetic binding assay 
• Determined the binding mechanisms by global fit analysis 
• Participated in writing of the manuscript  
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4.3. Combining kinetic binding mechanisms and thermodynamics to assess the selectivity of histone deacetylase inhibitors  Title: Impact of binding mechanism on selective inhibition of histone deacetylase isoforms.   Authors: Christian Meyners, Franz-Josef Meyer-Almes  Bibliographic Data: Submitted for publication in Chemical Biology and Drug Design  Abstract: Industrialized drug screening campaigns usually deliver hundreds of compounds that are active on a particular pharmaceutical target. In the light of high failure rates of drug candidates due to unforeseeable off-target toxicity, the early identification of the most promising compounds with high potential for target selectivity is an urgent need to improve the quality of lead compounds and lower attrition rates in the drug development process. The reliable prediction of the selectivity of active substances for a target protein is a challenging task. A comprehensive study of the binding kinetics, thermodynamics and selectivity of chemically related ligands of histone deacetylase (HDAC) like amidohydrolase from Pseudomonas aeruginosa (HDAHpa) reveals one general binding mechanism for all analyzed compounds consisting of a preceding conformational selection step followed by an optional subsequent induced fit. Depending on the chemical structure the ligands bind to one or two of at least three protein conformations with different rate constants. Although these kinetic and mechanistic differences hamper the predictability of selectivity for the HDAC inhibitors, we demonstrate that the enthalpy weighted binding constant KdΔH is a useful metric to predict isoform selectivity of inhibitors against HDAC enzymes and relatively robust toward different but related binding mechanisms.   Contributions by C. Meyners: 
• Produced the used proteins 
• Executed the kinetic binding assay, the ITC experiments and the enzyme activity assays 
• Determined the binding mechanisms by global fit analysis 
• Developed the enthalpy weighted binding constant 
• Wrote the manuscript 
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Title: Perflourinated hydroxamic acids are potent and selective inhibitors of HDAC-like enzymes from Pseudomonas aeruginosa.  Authors: Christian Meyners, Benjamin Wolff, Alexander Kleinschek, Andreas Krämer, Franz-Josef Meyer-Almes  Bibliographic Data: Bioorganic and Medicinal Chemistry Letters Volume 27, Issue 7, Pages 1508–1512, April 1, 2017. DOI: 10.1016/j.bmcl.2017.02.050  First published online: February 21, 2017  Abstract: A series of perfluorinated SAHA (PFSAHA) was prepared and profiled against a panel of human and bacterial members of the Histone deacetylase (HDAC) family. Some of the active substances show nanomolar inhibitory activity and several hundred fold selectivity for the HDAC like enzyme PA3774 from P. aeruginosa. The extraordinary selectivity against human HDACs results from the distinct oligomeric state of PA3774 which consists of two head-to-head dimers. The binding pocket is defined by the surface of both opposite monomers confining the access of ligands to the active site. In addition, the aromatic cap group of PFSAHA undergoes an edge-to-face aromatic interaction with phenylalanine from the opposite monomer.    Contributions by C. Meyners: 
• Produced some of the used proteins 
• Executed the enzyme activity assays   
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4.4. Parameters influencing the thermodynamics of the binding of histone deacetylase inhibitors  Title: The thermodynamic signature of ligand binding to histone deacetylase-like amidohydrolases is most sensitive to the flexibility in the L2-loop lining the active site pocket.   Authors: Christian Meyners, Andreas Krämer, Özkan Yildiz, Franz-Josef Meyer-Almes  Bibliographic Data: Biochimica et Biophysica Acta (BBA) - General Subjects 2017, DOI: http://dx.doi.org/10.1016/j.bbagen.2017.04.001 First published online: April 4, 2017  Abstract: Background The analysis of the thermodynamic driving forces of ligand-protein binding has been suggested to be a key component for the selection and optimization of active compounds into drug candidates. The binding enthalpy as deduced from isothermal titration calorimetry (ITC) is usually interpreted assuming single-step binding of a ligand to one conformation of the target protein. Although successful in many cases, these assumptions are oversimplified approximations of the reality with flexible proteins and complicated binding mechanism in many if not most cases. The relationship between protein flexibility and thermodynamic signature of ligand binding is largely understudied. Methods Directed mutagenesis, X-ray crystallography, enzyme kinetics and ITC methods were combined to dissect the influence of loop flexibility on the thermodynamics and mechanism of ligand binding to histone deacetylase (HDAC)-like amidohydrolases. Results The general ligand-protein binding mechanism comprises an energetically demanding gate opening step followed by physical binding. Increased flexibility of the L2-loop in HDAC-like amidohydrolases facilitates access of ligands to the binding pocket resulting in predominantly enthalpy-driven complex formation.    
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Conclusions The study provides evidence for the great importance of flexibility adjacent to the active site channel for the mechanism and observed thermodynamic driving forces of molecular recognition in HDAC like enzymes. General significance The flexibility or malleability in regions adjacent to binding pockets should be given more attention when designing better drug candidates. The presented case study also suggests that the observed binding enthalpy of protein-ligand systems should be interpreted with caution, since more complicated binding mechanisms may obscure the significance regarding potential drug likeness.   Contributions by C. Meyners: 
• Produced the used proteins 
• Performed the site-directed mutagenesis 
• Executed the ITC experiments and the enzyme activity assays 
• Participated in writing the manuscript  
 Cumulative Part  96  
 Cumulative Part  97  
 Cumulative Part  98  
 Cumulative Part  99  
 Cumulative Part  100  
 Cumulative Part  101  
 Cumulative Part  102  
 Cumulative Part  103  
 Cumulative Part  104   
 Supplemental Information  105 
5. Supplemental Information  This chapter provides the published supplemental information of the articles from section 4.  5.1 A fluorescence lifetime-based binding assay for acetylpolyamine amidohydrolases from  Pseudomonas aeruginosa using a [1,3]dioxolo[4,5-f]benzodioxole (DBD) ligand probe. Meyners C, Wawrzinek R, Krämer A, Hinz S, Wessig P, Meyer-Almes F-J. Anal. Bioanal. Chem. (2014) 406: 4889–4897  Available online at https://static-content.springer.com/esm/art%3A10.1007%2Fs00216-014-7886-5/MediaObjects/216_2014_7886_MOESM1_ESM.pdf  5.2  A fluorescence lifetime-based binding assay for class IIa histone deacetylases. Meyners C, Mertens M, Wessig P, Meyer-Almes F-J. Chem. Eur. J. (2017) 23: 3107–3116  Available online at http://onlinelibrary.wiley.com/store/10.1002/chem.201605140/asset/supinfo/chem201605140-sup-0001-misc_information.pdf?v=1&s=f5e2bcf283e848c8bc6aa59e54f1e596c270a482  5.3 Kinetic method for the large-scale analysis of the binding mechanism of histone deacetylase inhibitors. Meyners C, Baud MGJ, Fuchter MJ, Meyer-Almes F-J. Anal. Biochem. (2014) 460: 39–46  Available online at http://www.sciencedirect.com/science/MiamiMultiMediaURL/1-s2.0-S0003269714002255/1-s2.0-S0003269714002255-mmc1.docx/272363/html/S0003269714002255/4a4d10c607d91264d0ba4c3ed7a17d1c/mmc1.docx  5.4 Impact of binding mechanism on selective inhibition of histone deacetylase isoforms. Meyners C, Meyer-Almes F-J. Submitted for publication in Chemical Biology and Drug Design    
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5.5 Perflourinated hydroxamic acids are potent and selective inhibitors of HDAC-like enzymes from Pseudomonas aeruginosa. Meyners C, Wolff B, Kleinschek A, Krämer A, Meyer-Almes F-J. Bioorg. Med. Chem. Lett. (2017) 27: 1508–1512  Available online at http://www.sciencedirect.com/science/MiamiMultiMediaURL/1-s2.0-S0960894X17301828/1-s2.0-S0960894X17301828-mmc1.docx/271398/html/S0960894X17301828/cd041e413e28026992fdcdd78d3d4962/mmc1.docx  5.6 The thermodynamic signature of ligand binding to histone deacetylase-like amidohydrolases is  most sensitive to the flexibility in the L2-loop lining the active site pocket. Meyners C, Krämer A, Yildiz Ö, Meyer-Almes F-J. BBA - General subjects (2017)  DOI: http://dx.doi.org/10.1016/j.bbagen.2017.04.001  Available online at http://www.sciencedirect.com/science/MiamiMultiMediaURL/1-s2.0-S0304416517301265/1-s2.0-S0304416517301265-mmc2.docx/271022/html/S0304416517301265/706c7b066c10c5655479a0ecaed2eed8/mmc2.docx 
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6. Appendix  A Abrevations  APAH Acetylpolyamine deactylase CREB Cyclic AMP-responsive element-binding protein C-terminus Carboxy-terminus DAD Deacetylase activating domain from N-CoR1/2 Dansyl 5-(Dimethylamino)naphthalene-1-sulfonyl EC50 Concentration at which the effect is half maximal ERRα Steroid hormone receptor ERR1 FAHA (E)-3-(Furan-2-yl)-N-hydroxyacrylamide FK228 Romidepsin HAT Histone acetyltransferase Hda1 Histone deacetylase HDA1 HDAC Histone deacetylase HDAH Histone deacetylase-like amidohydrolase HDAHbo HDAH from Bordetella/Alcaligenes HDAHpa HDAH from Pseudomonas aeruginosa HDLP Histone deacetylase-like protein HSP90 Heat shock protein HSP 90 IC50 Concentration at which the inhibition is half maximal Ins(1,4,5,6)P4 Inositol 1,4,5,6-tetrakisphosphate Kd Equilibrium dissociation constant kobs observed rate constant koff dissociation rate constant kon association rate constant LBH589 Panobinostat M344 4-(Dimethylamino)-N-(7-(hydroxyamino)-7-oxoheptyl)-benzamide MTA1 Metastasis-associated proteins MTA1 N-CoR1/2 Nuclear receptor corepressor 1/2 NMR Nuclear magnetic resonance spectroscopy N-terminus Amino-terminus p53 Cellular tumor antigen p53 PFSAHA 2,2,3,3,4,4,5,5,6,6,7,7-Dodecafluoro-N1-hydroxy-N8-phenyloctanediamide 
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PXD101 Belinostat Rpd3 Histone deacetylase RPD3 SAHA Vorinostat SATFMK 9,9,9-Trifluoro-8-oxo-N-phenylnonanamide SIRT NAD-dependent protein deacetylase sirtuin SIN3 Paired amphipathic helix protein Sin3 TSA Trichostatin A    
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